Fiche centre
Novartis Investigative Site
Sendai — Japan
Essais liés6clinical trials
VilleSendailocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07517263
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05639114 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | ACTIVE_NOT_RECRUITING |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Iptacopan | Myasthénie | Phase 3 | NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | SIRIUS-SLE LTE — Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |